Metagenomi Reports Business Updates and Full Year 2024 Financial Results
Metagenomi, Inc. (MGX)
Company Research
Source: GlobeNewswire
Hemophilia A presentation at American Society of Hematology (ASH) 66th Annual Meeting demonstrated sustained Factor VIII (FVIII) activity in nonhuman primate (NHP) study for more than 16 months Leveraged hemophilia A albumin platform to achieve in vivo proof-of-concept in multiple secreted protein deficiencies to support wholly-owned follow-on program Progressed four Wave 1 Ionis targets to lead optimization with plans to declare one to two development candidates (DCs) in 2025 Well capitalized with $248.3 million in cash, cash equivalents and available-for-sale marketable securities at the end of Q4 2024; Cash runway anticipated to support operating plans into 2027 EMERYVILLE, Calif., March 17, 2025 (GLOBE NEWSWIRE) -- Metag
Read more
Impact Snapshot
Event Time:
MGX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
MGX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
MGX alerts
High impacting Metagenomi, Inc. news events
Weekly update
A roundup of the hottest topics
MGX
News
- Metagenomi, Inc. (NASDAQ: MGX) had its price target lowered by analysts at Wells Fargo & Company from $25.00 to $20.00. They now have an "overweight" rating on the stock.MarketBeat
- Metagenomi Announces Publication in Nature Communications on Large Gene Integration Advances Using Novel, Compact CRISPR-associated transposase (CAST) SystemsGlobeNewswire
- Metagenomi to Present at TD Cowen's 45th Annual Health Care ConferenceGlobeNewswire
- Totus Medicines Appoints Simon Harnest, MSc, BSc, as Chief Financial OfficerGlobeNewswire
- People are buying the wrong stock thinking it's part of OpenAI's Stargate Project [Yahoo! Finance]Yahoo! Finance
MGX
Earnings
- 11/13/24 - Beat
MGX
Sec Filings
- 3/26/25 - Form EFFECT
- 3/17/25 - Form 8-K
- 3/17/25 - Form S-3
- MGX's page on the SEC website